Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Access to Inhaled Pirfenidone (AP01) for Progressive Fibrosing Interstitial Lung Diseases
2024-515964-30-00Phase 2Completed
- Sponsor
- Avalyn Pharmaceuticals
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of pirfenidone in interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF), systemic sclerosis (SSc) and 2 more, sponsored by Avalyn Pharmaceuticals. Started Jul 2021; status: completed.
02
Drugs
pirfenidone
03
Conditions
interstitial lung disease (ILD)idiopathic pulmonary fibrosis (IPF)systemic sclerosis (SSc)Rheumatoid lung disease (RA-LD)silicosis
Beyond the preview
Go deeper on 2024-515964-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515964-30-00.